Gene transfer in cardiac myocytes

Surgical Clinics of North America

Volumn 84, Issue 1, 2004, Pages 141-159

  Chaudhri, Babar B ^a   Del Monte, Federica ^b   Harding, Sian E ^a   Hajjar, Roger J ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMID DNA; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ADENOVIRUS; ADRENERGIC SYSTEM; AMPLICON; BIOSYNTHESIS; CONGESTIVE HEART FAILURE; GENE DELIVERY SYSTEM; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENE VECTOR; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HERPES VIRUS; HUMAN; LENTIVIRINAE; MICROCIRCULATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SARCOPLASMIC RETICULUM; SIGNAL TRANSDUCTION;

EID: 1242293780     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6109(03)00209-3     Document Type: Review

References (78)

1. Ho K.K., Pinsky J.L., Kannel W.B., et al. The epidemiology of heart failure: the Framingham Study. Journal of the American College of Cardiology. 22:1993;6A-13A.
2. McKee P.A., Castell W.P., McNamara P.M., et al. The natural history of congestive heart failure, the Framingham Study. N Engl J Med. 285:1971;1441.
3. Murray C.J.L., Lopez A.D. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Circulation. 349:1997;226-233.
4. MacIntyre K., Capewell S., Stewart S., et al. Evidence of improving prognosis in heart failure: trends in case fatality in 66547 patients hospitalized between 1986 and 1995. Circulation. 102:2000;1126-1131.
5. Levy D., Kenchaiah S., Larson M.G., et al. Long term trends in the incidence and survival with heart failure. New Engl J Med. 347:2002;1397-1402.
6. Schroder F., Handrock R., Beuckelmann D.J., et al. Increased availability and open probability of single L-type calcium channels from failing compared with nonfailing human ventricle. Circulation. 98:1998;969-976.
7. Handrock R., Schroder F., Hirt S., et al. Single-channel properties of L-type calcium channels from failing human ventricle. Cardiovasc Res. 37:1998;445-455.
8. Studer R., Reinecke H., Bilger J., et al. Gene expression of the cardiac Na(+)-Ca2+ exchanger in end-stage human heart failure. Circ Res. 75:1994;443-453.
9. 2+ -ATPase in failing and nonfailing human myocardium. Circ Res. 75:1994;434-442.
10. Gwathmey J.K., Copelas L., MacKinnon R., et al. Abnormal intracellular calcium handling in myocardium from patients with End Stage Heart Failure. Cardiovasc Res. 61:1987;70-76.
11. Schillinger W., Kogler H. Altered phosphorylation and Ca2+-sensitivity of myofilaments in human heart failure. Cardiovasc Res. 57:2003;5-7.
12. Kinugawa S., Tsutsui H., Satoh S., et al. Role of Ca2+ availability to myofilaments and their sensitivity to Ca2+ in myocyte contractile dysfunction in heart failure. Cardiovasc Res. 44:1999;398-406.
13. Hajjar R.J., Gwathmey J.K. Cross-bridge dynamics in human ventricular myocardium. Regulation of contractility in the failing heart. Circulation. 86:1992;1819-1826.
14. Hajjar R.J., Grossman W., Gwathmey J.K. Responsiveness of the myofilaments to Ca2+ in human heart failure: implications for Ca2+ and force regulation. Basic Res Cardiol. 87:(Suppl 1):1992;143-159.
15. Tsutsui H. Oxidative stress in heart failure: the role of mitochondria. Intern Med. 40:2001;1177-1182.
16. Narula J., Haider N., Virmani R., et al. Apoptosis in myocytes in end-stage heart failure. N Engl J Med. 335:1996;1182-1189.
17. Narula J., Pandey P., Arbustini E., et al. Apoptosis in heart failure: release of cytochrome c from mitochondria and activation of caspase-3 in human cardiomyopathy. Proc Natl Acad Sci U S A. 96:1999;8144-8149.
18. Schwartz A., Lee K.S. Study of heart mitochondria and glycolytic metabolism in experimentally induced cardiac failure. Circ Res. 10:1962;321-332.
19. Takeshita S., Tsurumi Y., Couffinahl T., et al. Gene transfer of naked DNA encoding for three isoforms of vascular endothelial growth factor stimulates collateral development in vivo. Lab Invest. 75:1996;487-501.
20. Tsurumi Y., Takeshita S., Chen D., et al. Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion. Circulation. 94:1996;3281-3290.
21. Zhang G., Budker V.G., Ludtke J.J., et al. Naked DNA gene transfer in mammalian cells. Methods Mol Biol. 245:2004;251-264.
22. Hajjar R.J., del Monte F., Matsui T., et al. Prospects for gene therapy for heart failure. Circulation Research. 86:(6):2000;616-621.
23. Parks R.J. Improvements in adenoviral vector technology: overcoming barriers for gene therapy. Clin Genet. 58:2000;1-11.
24. Monahan P.E., Samulski R.J. Adeno-associated virus vectors for gene therapy: more pros than cons? Mol Med Today. 6:2000;433-440.
25. Buchschacher G.L. Jr., Wong-Staal F. Development of lentiviral vectors for gene therapy for human diseases. Blood. 95:2000;2499-2504.
26. Latchman D.S. Gene delivery and gene therapy with herpes simplex virus-based vectors. Gene. 264:2001;1-9.
27. Coffin R.S., Howard M.K., Cumming D.V., et al. Gene delivery to the heart in vivo and to cardiac myocytes and vascular smooth muscle cells in vitro using herpes virus vectors. Gene Therapy. 3:1996;560-566.
28. Davies C.H., Davia K., Bennett J.G., Pepper J.R., Poole-Wilson P.A., et al. Reduced contraction and altered frequency response of isolated ventricular myocytes from patients with heart failure. Circulation. 92:1995;2540-2549.
29. 2+ handling in myocardium from patients with end-stage heart failure. Circ Res. 61:1987;70-76.
30. 2+ -ATPase activity of cardiac sarcoplasmic reticulum from dilated cardiomyopathy patients compared with patients with nonfailing hearts. Circulation. 92:1995;3220-3228.
31. Limas C.J., Olivari M.-T., Goldenberg I.F., Levine T.B., Benditt D.G., Simon A. Calcium uptake by cardiac sarcolpasmic reticulum in human dilated cardiomyopathy. Cardiovasc Res. 21:1987;601-605.
32. 2+ -transporting ATPase, phospholamban, and calsequestrin levels in nonfailing and failing human myocardium. Circulation. 90:1994;653-657.
33. Feldman A.M., Ray P.E., Silan C.M., Mercer J.A., Minobe W., Bristow M.R. Selective gene expression in failing human heart: quantification of steady-state levels of messenger RNA in endomyocardial biopsies using the polmerase chain reaction. Circulation. 83:1991;1866-1872.
34. 2+ -ATPase in failing and nonfailing human hearts. Cardiovasc Res. 31:1996;625-632.
35. Meyer M., Schillinger W., Pieske B., Holubarsch C., Heilmann C., Posival H., et al. Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. Circulation. 92:1995;778-784.
36. Davia K., Davies C.H., Harding S.E. Effects of inhibition of sarcoplasmic reticulum calcium uptake on contraction of myocytes from failing human ventricle. Cardiovasc Res. 33:1997;88-97.
37. Schwinger R.H., Brixius K., Bavendiek U., Hoischen S., Muller-Ehmsen J., Bolck B., et al. Effect of cyclopiazonic acid on the force frequency relationship in human non-failing myocardium. J Pharmacol Exp Ther. 283:1997;286-292.
38. Bavendiek U., Brixius K., Munch G., Zobel C., Muller-Ehmsen J., Schwinger R.H. Effect of inotropic interventions on the force-frequency relation in the human heart. Basic Res Cardiol. 93:(Suppl 1):1998;76-85.
39. 2+ -ATPase with phospholamban in phospholipid vesicles. J Biol Chem. 265:1990;1702-1709.
40. 2+ pump of sarcoplasmic reticulum. Nature. 342:1989;90-92.
41. Kranias E.G., Solaro R.J. Phosphorylation of troponin I and phospholamban during catecholamine stimulation of rabbit heart. Nature. 298:1982;182-184.
42. Wegener A.D., Simmerman H.K., Lindemann J.P., Jones L.R. Phospholamban phosphorylation in intact ventricles. Phosphorylation of serine 16 and threonine 17 in response to beta-adrenergic stimulation. J Biol Chem. 264:1989;11468-11474.
43. Garvey J.L., Kranias E.G., Solaro R.J. Phosphorylation of C-protein, troponin I and phospholamban in isolated rabbit hearts. Biochem J. 249:1988;709-714.
44. 2+ -calmodulin-dependent mechanisms. J Biol Chem. 260:1985;4516-4525.
45. Talosi L., Edes I., Kranias E.G. Intracellular mechanisms mediating reversal of β-adrenergic stimulation in intact beating hearts. Am J Physiol. 264:1993;H791-H797.
46. Koss K.L., Grupp I.L., Kranias E.G. The relative phospholamban and SERCA2 ratio: a critical determinant of myocardial contractility. Basic Res Cardiol. 92:(Suppl 1):1997;17-24.
47. del Monte F., Harding S.E., Schmidt U., Matsui T., Kang Z.B., Dec G.W., et al. Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a. Circulation. 100:1999;2308-2311.
48. Miyamoto M.I., del Monte F., Schmidt U., DiSalvo T.S., Kang Z.B., Matsui T., et al. Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. Proc Natl Acad Sci USA. 97:2000;793-798.
49. 2+ -ATPase. Circulation. 101:2000;790-796.
50. 2+ overlaod and enhances viability. Circulation. 100:1999;4030.
51. Davia K., Bernobich E., Ranu H.K., del Monte F., Terracciano C.M.N., MacLeod K.T., et al. SERCA2a overexpression decreases the incidence of aftercontractions in adult rabbit ventricular myocytes. J Mol Cell Cardiol. 2001;1005-1015.
52. 2+ -ATPase in a rat model of heart failure. Circulation. 104:2001;1424-1429.
53. 2+ cycling differentially affect the progression of cardiomyopathy. J Clin Invest. 107:2001;967-974.
54. 2+ cycling defect in dilated cardiomyopathy. Cell. 99:1999;313-322.
55. Luo W., Grupp I.L., Ponniah S., Grupp G., Duffy J.J., Doetschman T., et al. Targeted ablation of the phopholamban gene is associated with markedly enhanced myocardial contractility and loss of β-Agonist stimulation. Circ Res. 75:1994;401-409.
56. Slack J.P., Grupp I.L., Dash R., Holder D., Schmidt A., Gerst M.J., et al. The enhanced contractility of the phospholamban-deficient mouse heart persists with aging. J Mol Cell Cardiol. 33:2001;1031-1040.
57. 2+. Am J Physiol. 271:1996;C391-C397.
58. Luo W., Wolska B.M., Grupp I.L., Harrer J.M., Haghighi K., Ferguson D.G., et al. Phospholamban gene dosage effects in the mammalian heart. Circ Res. 78:1996;839-847.
59. Chu G., Luo W., Slack J.P., Tilgmann C., Sweet W.E., Spindler M., et al. Compensatory mechanisms associated with the hyperdynamic function of phospholamban-deficient mouse hearts. Circ Res. 79:1996;1064-1076.
60. Li L., Chu G., Kranias E.G., Bers D.M. Cardiac myocyte calcium transport in phospholamban knockout mouse: relaxation and endogenous CaMKII effects. Am J Physiol. 274:1998;H1335-H1347.
61. Santana L.F., Kranias E.G., Lederer W.J. Calcium sparks and excitation-contraction coupling in phospholamban-deficient mouse ventricular myocytes. J Physiol. 503:1997;21-29.
62. Lorenz J.N., Kranias E.G. Regulatory effects of phospholamban on cardiac function in intact mice. Am J Physiol. 273:1997;H2826-H2831.
63. Sato Y., Kiriazis H., Yatani A., Schmidt A.G., Hahn H., Ferguson D.G., et al. Rescue of contractile parameters and myocyte hypertrophy in calsequestrin overexpressing myocardium by phospholamban ablation. J Biol Chem. 276:2001;9392-9399.
64. del Monte F., Harding S.E., Dec G.W., Gwathmey J.K., Hajjar R.J. Targeting Phospholamban in Human Heart Failure by Gene Transfer. Circulation. 105:2002;904-907.
65. Chaudhri B., del Monte F., Hajjar R.J., Harding S.E. Interaction between increased SERCA2a activity and β-adrenoceptor stimulation in adult rabbit myocytes. Am J Physiol. 283:2002;2450-2457.
66. Tweedie D., O'Gara P., Harding S.E., MacLeod K.T. The effect of alterations to action potential duration on β-adrenoceptor-mediated after-contractions in human and guinea-pig ventricular myocytes. J Mol Cell Cardiol. 29:1997;1457-1467.
67. Benovic J.L., Bouvier M., Caron M.G., Lefkowitz R.J. Regulation of adenylate cyclase coupled β-adrenergic receptors. Annu Rev Cell Biol. 4:1988;405-428.
68. Ungerer M., Bohm M., Elce J.S., Erdmann E., Lohse M.J. Altered expression of β-adrenergic receptor kinase and β1-adrenergic receptors in the failing human heart. Circulation. 87:1993;454-463.
69. Brown L.A., Harding S.E. The effect of pertussis toxin on β-adrenoceptor responses in isolated cardiac myocytes from noradrenaline-treated guinea-pigs and patients with cardiac failure. Br J Pharmacol. 106:1992;115-122.
70. Feldman A.M., Cates A.E., Veazey W.B., Hershberger R.E., Bristow M.R., Baughman K.L., et al. Increase of the 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart. J Clin Invest. 82:1988;189-197.
71. Waagstein F., Bristow M.R., Swedberg K., Camerini F., Fowler M.B., Silver M.A., et al. Beneficial effects of metoprolol in idiopathic dilated cardimyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet. 342:1993;1441-1446.
72. CIBIS Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet. 353:1999;9-13.
73. CIBIS Investigators and Committees. A randomized trial of β-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation. 90:1994;1765-1773.
74. Packer M., Bristow M.R., Cohn J.N., Colucci W.S., Fowler M.B., Gilbert E.M., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 334:1996;1349-1355.
75. Cohn J.N., Fowler M.B., Bristow M.R., Colucci W.S., Gilbert E.M., Kinhal V., et al. Safety and efficacy of carvedilol in severe heart failure. The US Carvedilol Heart Failure Study Group. J Card Fail. 3:1997;173-179.
76. Heidenreich P.A., Lee T.T., Massie B.M. Effect of β-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J Am Coll Cardiol. 30:1997;27-34.
77. Maurice J.P., Hata J.A., Shah A.S., White D.C., McDonald P.H., Dolber P.C., et al. Enhancement of cardiac function after adenoviral-mediated in vivo intracoronary β2-adrenergic receptor gene delivery. J Clin Invest. 104:1999;21-29.
78. 2+ pump ATPase. J Biol Chem. 267:1992;1674-1679.